Medical/Pharmaceuticals
OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab
SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. ("OEP"). According to the terms of th...
2023-03-28 15:36
1672
Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors
ALAMEDA, Calif. and TAIPEI, March 27, 2023 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation of new ...
2023-03-28 10:00
1577
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
SHANGHAI, March 27, 2023 /PRNewswire/ -- BJ Bioscience, Inc. BJ Bioscience, a biotech company focusing on discovery and development of novel biologics for cancer immunotherapy, today announced that it entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.,Rah...
2023-03-28 09:19
1635
Noul Co. Ltd - The RIGHT Foundation Commences Research and Development for Supporting Malaria Control
* Aim to accelerate global business and access to the public market based on reliable research results * Grant funds will be utilized for global clinical studies and cost-effectiveness analysis of the miLab™ Platform over the next three years YONGIN,South Korea, March 27, 2023 /PRNewswire/ --...
2023-03-27 21:00
1566
Berry Genomics and Ajlan & Bros Holding Subsidiaries Establish a Joint Venture to Support 'Vision 2030'
BEIJING, March 27, 2023 /PRNewswire/ -- Xcelom Limited, a subsidiary of Berry Genomics, has recently signed a cooperation agreement with Ajlan & Bros Medical Company, an Ajlan &Bros Holding subsidiary, to establish a joint venture that will supportSaudi Arabia's "Vision 2030." The joint venture ...
2023-03-27 20:46
1732
BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies
Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform -BDDS™ - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PR...
2023-03-27 20:00
1394
PharmaBlock Opens New R&D Facility in Pennsylvania -- Expanding Capacity to Deliver GMP Projects
WEST CHESTER, Pa., March 27, 2023 /PRNewswire/ -- PharmaBlock (stock code: 300725.SZSE), a global, fully integrated CDMO company focused on innovative chemistry and low-carbon manufacturing, announces the opening of its new R&D facility inWest Chester, Pennsylvania. The facility expands the comp...
2023-03-27 20:00
1754
ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting
WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential, will present two posters from its lead program, PRO1184, a folate receptor alpha (FRα)-...
2023-03-24 20:00
3228
Clear Medical Imaging and See-Mode Technologies Announce Partnership via CureLabs Innovation Hub
MELBOURNE, Australia, March 23, 2023 /PRNewswire/ -- Clear Medical Imaging, a leading provider of radiology services and the second largest independent healthcare provider inOntario, announces partnership with See-Mode Technologies to adopt See-Mode, an artificial intelligence (AI) software appli...
2023-03-23 21:00
1950
AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023
NEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platf...
2023-03-23 20:00
2853
111, Inc. Announces Fourth Quarter and Fiscal Year 2022 Financial Results
SHANGHAI, March 23, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the fourth qua...
2023-03-23 14:17
2967
Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition Towards Biopharma
SUZHOU, China and ROCKVILLE, Md., March 22, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During...
2023-03-23 00:22
3001
Jacobio Pharma Announces 2022 Annual Results
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced its 2022 annual results. R&D investment wasRMB530 million, showing an increase of 26% compared with 2021. The revenue wasRMB95.7 million, which was generated from an out-licensing deal. Jacobio Pharma ...
2023-03-22 22:38
3268
Jolly Good and Harvard University Hospital collaborate on medical VR - Full-scale entry into the U.S. market
~ Dr. Kei Ouchi, Associate Professor of Medicine at Harvard Medical School, appointed as Jolly Good Medical Advisor ~ TOKYO, March 22, 2023 /PRNewswire/ -- (Chuo-ku, Tokyo; President: Kensuke Joji ; hereinafter "Jolly Good"), in collaboration with Brigham and Women's Hospital (Boston, Massachuset...
2023-03-22 21:00
2123
CARsgen Announced 2022 Annual Results and Business Updates
SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results. Business Highlights * Zevor-cel (CT053)...
2023-03-22 20:50
2195
Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023
NEWARK, Del., March 22, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-507: anti-PD1ⅹanti-PVRIG bispecific antibody and BSI-508: anti-PD1ⅹanti-CD47 bis...
2023-03-22 20:19
1671
WuXi Biologics Reports Remarkable 2022 Annual Results
Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million Adjusted Net Profit Rose by 47.1% to RMB5,053.9 Million Non-COVID Revenue Achieved 63% Y-o-Y Growth, Strong Momentum Continues into 2023 and Beyond "R" in CRDMO Business Model A...
2023-03-22 20:09
3140
Zylox-Tonbridge Assisted Turkish Hospitals in Post-earthquake Recovery
HANGZHOU, China, March 22, 2023 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, "the Company"), one of the leading players in the neuro- and peripheral-vascular interventional medical device market inChina , announced its plans to provide free replacement services for produc...
2023-03-22 15:26
1961
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer
BEIJING, SHANGHAI and BOSTON, March 22, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc.,Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Ra...
2023-03-22 12:36
2022
280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting
A broadly acting KRAS Inhibitor, TEB-17231, robustly blocks tumor growth and overcomes KRASG12C inhibitor mediated resistance SHANGHAI, March 21, 2023 /PRNewswire/ -- 280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced ...
2023-03-21 20:00
1562
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400